California Cancer Registry Reportability Guide

REPORTABLE TERMS

Ambiguous Terminology

Considered as Diagnostic of Cancer

Exception: If the cytology is reported as “suspicious” and neither a positive biopsy nor a phy sician’s clinical impression supports the cytology findings, do not consider as diagnosis of cancer.

The Reportable terms noted above are used ONLY for reportability. These are not to be used for determining tumor extension/involvement or for determining histological classification. There are separate lists for those.

SITE SPECIFIC REPORTABILITY GUIDE

Site

Histology

Reference

Reportable/Non-reportable Criteria

SKIN

C44.0-C44.9

8000-8110

Volume One: II.2.3 Skin Reportability

Always been non-reportable

• Basal cell carcinomas of the skin.

• Epithelial carcinomas of the skin.

• Papillary carcinomas of the skin.

• Squamous cell carcinomas of the skin.

• Early Melanoma.  

• Evolving Melanoma.  

EXCEPTIONS: Reportable skin cancers include:

• Skin cancers in the genital sites (any histology): (vagina (C52.9); clitoris (C51.2); labium (C51.0); vulva (C51.9); prepuce (C60.0); penis (C60.9) and scrotum (C63.2) are reportable.

• All other malignant tumors of the skin, such as adnexal carcinomas (e.g., carcinomas of the sweat gland, sebaceous gland, ceruminous gland, and hair follicle), adenocarcinomas, lymphomas, melanomas, sarcomas, and Merkel cell tumors are reportable regardless of site. Any carcinoma arising in a hemorrhoid is reportable since hemorrhoids arise in mucosa, not in the skin.

• “Early melanoma insitu” and “Evolving melanoma insitu” NOTE: These terms must be stated exactly as stated here. The “insitu” behavior must be included in diagnosis in order for these to be reportable.  No variation in terms allowed.

CERVIX

C53.0-C53.9

Any morphology

with behavior 2

Volume One: II.1 Reportability Guide

Reportable = Before 1996

• Carcinoma in situ of the cervix (CIS) (including squamous cell & adenocarcinoma).

• Cervical Intraepithelial Neoplasia grade III (CIN III).

• Cervical Intraepithelial Neoplasia with severe dysplasia (CIN III).

BENIGN BRAIN (NOTE: Benign Schwannoma section below)

C70.0-70.9

C71.0-71.9

C72.0-C72.9

C75.1-C75.3

Behavior = 0 or 1

Volume One: II.2.7

Reportability

Reportable = 2001+

Hemangioma, NOS and cavernous hemangiomas (9120/0 or 9121/0)

SEER Program Manual- Reportability  

SEER INQ #20130001

Reportable = 2001+

• Standard Difference: CCR reportability date for benign brains is 2001; national date is 2004.

• Juvenile astrocytoma is coded as borderline in ICD-O-3; North America registries report as 9421/3. (per ICD-O-3 Errata dated 5/22/2001)

BENIGN SCHWANNOMAS

C72.2-72.5

9560

Behavior=0

SEER and CDC

Reportable = 2004+ (only report Site codesC72.2-72.5)

C72.0

9560

Behavior=0

SEER SINQ #20130023

Reportable = 2011+ (expanded to include site code C72.0)

Per SEER Instruction, we are to report Benign Schwannomas (9560/0) of the spinal cord (C72.0) and of the cranial nerves (C72.2 - C72.5); therefore, these are both reportable to the CCR.  Benign Schwannomas occurring anywhere else such as the peripheral nerves or spinal nerves are not reportable to the CCR.        

BORDERLINE OVARIAN

C56.9

8442/1

8451/1

8462/1

8472/1

8473/1

Volume One: II.2.8 Borderline Ovarian Tumors

Always been reportable either as a behavior /3 for pre-2001 or behavior /1 for 2001+

INTRAEPITHELIAL NEOPLASIA

AIN III (anal intraepithelial neoplasia)

C21.0

C21.1

8077/2

Volume One: V.3.4.1 In Situ

Coding

DSQC Memo #2001-03

DSQC Memo #2002-01

PAQC Memo #2012-03

Reportable = 2001+

DIN 3 (ductal intraepithelial neoplasia 3)

C50.__

8500/2

Volume One: V.3.4.1 In Situ

Coding

DSQC Memo #2002-01

Reportable = 2001+

LIN III (laryngeal intraepithelial neoplasia)

C32.    

8077/2

Volume One: V.3.4.1 In Situ

Coding

DSQC Memo #2002-01

Reportable = 2001+

PanIN-III (pancreatic intraepithelial neoplasia III)

C25.    

8500/2

Volume One: V.3.4.1 In Situ

Coding

Reportable = 2004+

PeIN III (penile intraepithelial neoplasia)

C60._

8077/2

8148/2

Volume One: V.3.4.1 In Situ

Coding

Reportable = 2001+

PIN III (prostatic intraepithelial neoplasia)

C61.9

8148/2

Volume One: V.3.4.1 In Situ

Coding

Has never been reportable to the CCR

SIN III (squamous intraepithelial neoplasia)

All sites (Excluding Cervix)

8077/2

Volume One: V.3.4.1 In Situ Coding

SEER Program Manual 2014

Reportable = 2014+

VAIN III (vaginal intraepithelial neoplasia)

VIN III  (vulvar intraepithelial neoplasia)

C52._

C51._

8077/2

Volume One: V.3.4.1 In Situ

Coding

DSQC Memo #2002-01

PAQC Memo #2012-03

Reportable = 1992+

LYMPHATIC & HEMATOPOIETIC DISEASES---SUBSEQUENT DIAGNOSES

DATE DIAGNOSIS YEAR

1st Primary

2nd primary

Reference

Prior to 2001

Prior to 2001

ICD-O-2 table in Volume I, II.1.3 (ICD-O-2 rules)

2001--2009

2001--2009

ICD-O-3 table in Volume I, Appendix R (2001 Single Versus Subsequent

Primaries of Lymphatic and Hematopoietic Diseases table)

Prior to 2001

2001-2009

ICD-O-3 table in Volume I, Appendix R (2001 Single Versus Subsequent

Primaries of Lymphatic and Hematopoietic Diseases table)

2010

2010

SEER Hematopoietic Manual & Database

Prior to 2010

2010

SEER Hematopoietic Manual & Database

Clarification on Reportability

Carcinoid tumors, NOS of the Appendix (C18.1)  

8240/3 effective with 2015

8240/1 is obsolete in 2015

ICD-O-3 Updates 2015  

SEER Program Manual- Reportability  

Reportable = 2015 +  

Dysplasia (severe, high grade)

Only reportable when it is specified as carcinoma in situ or pathologist documents as being synonymous with carcinoma in situ.

GIST – Gastrointestinal stromal tumors

Only reportable if identified as being in situ or malignant. SEER INQ #20140088

Lymphoma In situ   

SEER Hematopoietic Manual & Database

SEER SINQ #20130042

Has always been non-reportable  

PUNLMP – Papillary Urothelial Neoplasm of Low Malignant Potential

Not reportable. Pre malignant growths in the upper urinary tract (renal pelvis, ureters, urinary bladder part of urethra).

Pancreas (C25.0-C25.9)

Neuroendocrine tumor when dx is insulinoma (8240/3 or 8151/3)

Cystic pancreatic endocrine neoplasm (CPEN) (8150/3)

Cystic pancreatic endocrine neoplasm specified as neuroendocrine tumor, Grade 1 (8240/3)

Cystic pancreatic endocrine neoplasm specified as neuroendocrine tumor, Grade 2 (8249/3)

Solid pseudopapillary neoplasm of pancreas (8452/3)

Non-invasive mucinous cystic neoplasm (MCN) pf pancreas with high grade dysplasia (8470/2)

NOTE: Term high-grade dysplasia replaces term mucinous cystadenocarcinoma, non-invasive  

Pituitary Gland (C75.1)  

Rathke pouch tumor (9350/1)

NOTE: Rathke cleft cyst and Rathke pouch tumor are different conditions. Rathke cleft cyst is not reportable.  

Reportable = 2001 +

Testes (C62.0-C62.9)

Mature teratoma of testes in adult

Adult defined as post puberty

NOTE: Do not report if it is unknown whether patient is pre or post pubescence.  

 Reportable = 2015 +

Urine cytology - Positive for malignancy

SEER Program Manual- Reportability  

SEER INQ #20120079

Volume  One: II.1.6 Reportable Terms  

Reportable = 2013 +

Venous angioma /Venous hemangioma

Venous angiomas are NOT reportable wherever they arise.  The primary site for venous hemangioma arising in the brain is blood vessel (C490). The combination of 9122/0 (Venous Hemangioma) and C490 is not reportable.

NOTE:  This is a venous abnormality, previously referred to as venous angiomas and currently referred to as developmental venous anomalies (DVA)